HLB's FDA Breakthrough: How a $5M Acquisition Beat Three Rejections

The Limit-Up Moment

HLB’s shares climbed 29.95 percent on September 28, closing at 39,700 won and hitting the upper price limit for the second consecutive session. The move wasn’t driven by revenue guidance or a blockbuster pipeline update. It followed a single sentence from the U.S. Food and Drug Administration: a new indication for a drug HLB didn’t invent.

The approval came for lirapu gratinib, marketed as Refictu, a targeted therapy for cholangiocarcinoma—cancer of the bile ducts. HLB’s U.S. subsidiary, Elavate Therapeutics, filed the application. The FDA granted it on September 23, after a review period that included a request for additional dose-comparison data.

For HLB, the approval is a milestone and a mirror. It arrives three years after the company began chasing its own revoceranib program through the same regulatory gate, only to receive three complete response letters citing manufacturing-quality defects. Refictu, by contrast, entered HLB’s portfolio as a finished asset, purchased from Relay Therapeutics in December 2024 for a $5 million upfront payment and up to $500 million in contingent payments plus low-double-digit royalties.

The stock market rewarded the pivot. HLB Pharmaceutical, HLB Life Science, and HLB Therapeutics all hit daily price limits on the same day. The broader signal is less about one company and more about a strategy that now looks replicable.

What Got Approved

Refictu targets FGFR2 fusions and rearrangements, alterations found in roughly 10 to 15 percent of intrahepatic cholangiocarcinoma cases. The approval covers adults whose disease has progressed after prior treatment and for whom surgery is no longer an option.

The pivotal data came from a combined phase 1/2 study of 116 patients. The objective response rate was 46 percent, with a median duration of response of 11.8 months. Those numbers are competitive within the FGFR inhibitor class and notably higher than what historically been observed with pan-FGFR agents, which tend to carry greater on-target toxicity.

The FDA did not approve Refictu without conditions. It mandated a randomized post-approval study comparing the currently recommended 70 milligram daily dose against a lower dose, with endpoints focused on safety and efficacy. The study must be completed by November 2031. The agency also flagged existing class effects—stomatitis, hand-foot syndrome, nail toxicity, and retinal disorders—as ongoing evaluation targets.

Elavate plans to launch Refictu in the United States during the fourth quarter of this year. Commercial scale will be modest. Cholangiocarcinoma is a rare cancer, and the approved population is narrow. Even at peak sales, the drug is unlikely to exceed $500 million annually in the U.S., based on comparable oncology niche indications.

The Rejection That Preceded It

HLB’s path to Refictu’s approval was paved with its own failures. The company spent nearly two decades developing revoceranib, a kinase inhibitor intended for hepatocellular carcinoma. In July, the FDA issued a third complete response letter, again citing deficiencies in the manufacturing facility’s current good manufacturing practice compliance. HLB stated it would address the cited issues and resubmit.

The revoceranib program also included a combination with camrelizumab, a PD-1 inhibitor from China’s Jiangsu Hengrui Medicine. That combination never advanced beyond the CRL stage.

Three rejections from the same agency, the same drug, the same issue: not efficacy, but process. For a company that built its public narrative on revoceranib, the pattern was humiliating and expensive. The Refictu approval does not erase that record. It sidesteps it.

The Acquisition Template

What makes this moment structurally interesting is not that HLB won. It is that HLB won by changing the game.

The deal with Relay Therapeutics follows a formula that has gained traction among Seoul-listed biotechs over the past three years: acquire a late-stage asset from a smaller U.S. or European biotech, secure the global rights, and commercialize in Korea and other Asian markets while pursuing FDA approval for the U.S.

The economics are straightforward. The upfront cost is small. The contingent payments scale with regulatory and commercial milestones. The royalty structure aligns incentives. The risk shifts from discovery to execution—a different risk, but one that HLB appears better positioned to manage after its manufacturing struggles with revoceranib.

This model is not without critics. Some analysts have argued that buying approved or near-approved assets commoditizes Korean biotech and reduces the premium of indigenous innovation. The counterargument is pragmatic: FDA approval is the hard gate. Assets that have already passed phase 3 trials andINDEnrollment face a lower regulatory hurdle than early-stage programs. For a sector where capital is scarce and listing expectations are high, the acquisition route offers a faster, more predictable path to revenue.

HLB’s stock reaction suggests investors agree. The limit-up days reflect a re-rating of the company’s risk profile, not just excitement over a single drug.

Who Wins, Who Loses

Winners:

• HLB shareholders, who now hold an FDA-approved oncology asset with commercial launch imminent.
• Patients with FGFR2-altered cholangiocarcinoma, who gain access to a targeted therapy that was previously unavailable in Korea.
• Korean biotech investors who view acquisition-led pipelines as a viable alternative to de novo development.
• Relay Therapeutics, which converted a stalled asset into $5 million immediate cash and up to $500 million in potential upside.

Losers:

• Companies that continue to rely exclusively on internal R&D without considering late-stage acquisitions, especially those facing similar manufacturing quality challenges.
• Revoceranib’s developers, who must now compete with a drug that holds FDA approval in a related oncology indication.
• Analysts who priced HLB as a pure play on revoceranib success; the company’s valuation multiple will likely adjust to reflect a dual-engine pipeline.

The Bigger Shift

The approval does not solve HLB’s underlying problem: its homegrown revoceranib program remains stuck in regulatory limbo. The company has not disclosed a timeline for resubmission beyond stating it will fix the manufacturing deficiencies.

What the Refictu approval does solve is a narrative problem. For years, Korean biotech has been portrayed as strong in fast-follow generics and weak in first-in-class innovation. The sector’s market capitalizations have reflected that bias. An FDA approval—even for an acquired asset—challenges the stereotype.

More importantly, it provides a blueprint. Other companies with stalled IND programs or manufacturing setbacks can now point to HLB’s deal and argue that acquisition is not a retreat but a rational reallocation of capital.

This shift will reshape pipeline risk across the Seoul-listed pharma sector. Companies that once viewed late-stage acquisition as a sign of desperation may soon treat it as a standard portfolio management tool. Capital allocation committees will weigh internal burn rates against milestone premiums. Clinical development teams will begin negotiating with U.S. biotechs as a matter of course, not as a last resort.

What Comes Next

Refictu’s commercial trajectory will depend on several factors: speed of U.S. launch, reimbursement negotiations, physician adoption in a niche indication, and the outcome of the mandated post-approval dose study. The lower-dose arm could expand the addressable population if safety signals favor it.

For HLB, the immediate priority is resolving the revoceranib manufacturing issues. A fourth CRL would damage credibility far more than the Refictu approval can repair. The company’s next earnings call will likely focus on how it balances a legacy program with a new commercial asset.

Regulators in other markets may also take note. The FDA approval could streamline path to EMA or PMDA submissions, though each agency will evaluate the same post-approval study requirements differently.

The stock price jump is a snapshot. The real test will be whether HLB can translate this approval into sustained revenue growth and whether other Korean biotechs can replicate the model without repeating the same manufacturing stumbles that plagued revoceranib.

If they can, the implication is clear: the next wave of Korean biotech value may not come from laboratories in Pangyo, but from term sheets signed in Boston.

The Bottom Line

HLB’s FDA approval of lirapu gratinib is a milestone not because it cures a difficult cancer, but because it proves a strategy. In a sector where innovation is prized and acquisition is often sneered at, HLB has shown that buying a validated asset can be smarter than building one from scratch—especially when the build path keeps hitting the same wall.

The limit-up days are just the opening move. The rest of the game will be played in clinics, boardrooms, and regulatory filings over the next five years.

For Korean biotech, the lesson is simple: the gatekeeper is not always the lab. Sometimes it is a license agreement.